Drug · CHEMBL494
ILOPROST
7 sourcespipelines-2026-09-18-0.3.1
Cite this record
ConductScience Library. ILOPROST. Drugs and targets, record CHEMBL494. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL494
On this page
Drug
Names and IDs as ChEMBL gives them, through Open Targets.
- Open Targets' highest stage
- Approval, for 3 of its 25 diseases, from ATC, DailyMed, EMA Human Drugs, PMDA and TTD
- Open Targets
Targets1
The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.
| Target | Protein | Mechanism | Action | Gene in Genes |
|---|---|---|---|---|
| PTGIR | Prostacyclin receptor | Prostanoid IP receptor agonist | AGONIST | https://conductscience.org/library/genes/5739 |
Source ChEMBL
Diseases25
The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Disease | Open Targets' stage | Stage reported by | Reports | Of them trials | Its drugs |
|---|---|---|---|---|---|
| pulmonary arterial hypertension | Approval | DailyMed, PMDA and TTD | 28 | 25 | https://conductscience.org/library/drugs?q=MONDO_0015924 |
| pulmonary hypertension | Approval | EMA Human Drugs | 22 | 21 | https://conductscience.org/library/drugs?q=MONDO_0005149 |
| acute respiratory distress syndrome | Phase 3 | ClinicalTrials.gov | 5 | 5 | https://conductscience.org/library/drugs?q=MONDO_0006502 |
| chronic obstructive pulmonary disease | Phase 2 | ClinicalTrials.gov | 4 | 4 | https://conductscience.org/library/drugs?q=MONDO_0005002 |
| Hypoxemia | Unknown | ClinicalTrials.gov | 3 | 3 | https://conductscience.org/library/drugs?q=HP_0012418 |
| idiopathic pulmonary arterial hypertension | Phase 3 | ClinicalTrials.gov | 3 | 3 | https://conductscience.org/library/drugs?q=MONDO_0001999 |
| septic shock | Phase 3 | ClinicalTrials.gov | 3 | 3 | https://conductscience.org/library/drugs?q=EFO_0006834 |
| respiratory failure | Phase 2 | ClinicalTrials.gov | 2 | 2 | https://conductscience.org/library/drugs?q=MONDO_0021113 |
| COVID-19 | Phase 2 | ClinicalTrials.gov | 1 | 1 | https://conductscience.org/library/drugs?q=MONDO_0100096 |
| Thickened skin | Phase 2 | ClinicalTrials.gov | 1 | 1 | https://conductscience.org/library/drugs?q=HP_0001072 |
1 to 10 of 25Source Open Targets
See all 25 diseasesTrials92
Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs.
| Trial | Title | Phase | Participants | Results first posted | Named as | Linked by | Source |
|---|---|---|---|---|---|---|---|
| NCT04040322 | Intravenous Iloprost in Subjects With Symptomatic Raynaud's Phenomenon Secondary to Systemic Sclerosis (Phase 3) | Phase 3 | 198 | 2025-05-25 | iloprost | Its name | ClinicalTrials.gov |
| NCT00084409 | Iloprost in Preventing Lung Cancer in Patients at High Risk for This Disease | Phase 2 | 152 | 2013-02-13 | iloprost | Its name | ClinicalTrials.gov |
| NCT00302211 | The "VISION" Trial: Ventavis Inhalation With Sildenafil to Improve and Optimize Pulmonary Arterial Hypertension | Phase 3 | 67 | 2010-08-13 | iloprost | Its name | ClinicalTrials.gov |
| NCT00709956 | Iloprost Power 15 in Pulmonary Arterial Hypertension | Phase 3 | 64 | 2012-10-26 | iloprost | Its name | ClinicalTrials.gov |
| NCT00723554 | Iloprost Power Disc-15 in Pulmonary Arterial Hypertension | Phase 3 | 63 | 2013-02-15 | iloprost | Its name | ClinicalTrials.gov |
| NCT00467896 | The "Power 15 Study": Safety Study of Inhalation of Ventavis With the Power Disc-15 Setting | Phase 2 | 62 | 2012-10-26 | iloprost | Its name | ClinicalTrials.gov |
| NCT00709098 | Safety Study Extension of Iloprost Power 15 in Pulmonary Arterial Hypertension | Phase 3 | 49 | 2012-10-29 | iloprost | Its name | ClinicalTrials.gov |
| NCT03867097 | Intravenous Iloprost in Subjects With Symptomatic Raynaud's Phenomenon Secondary to Systemic Sclerosis (Phase 2) | Phase 2 | 34 | 2025-05-25 | iloprost | Its name | ClinicalTrials.gov |
| NCT02170519 | Inhaled Aerosolized Prostacyclin for Pulmonary Hypertension Requiring Inhaled Nitric Oxide | Phase 4 | 27 | 2014-08-26 | iloprost | Its name | ClinicalTrials.gov |
| NCT03044314 | Outpatient Vasodilator Assessment Using Iloprost in Pulmonary Hypertension | Phase 4 | 27 | 2024-04-02 | iloprost | Its name | ClinicalTrials.gov |
1 to 10 of 92
See all 92 trialsComparisons in its trials12
Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Iloprost Injection, for Intravenous Use vs Placebo: Percentage of Responders | 33 of 99 | 33 of 97 | 196 | NCT04040322 | Trial comparisons |
| Iloprost Injection, for Intravenous Use vs Placebo: deaths from any cause | 0 of 99 | 0 of 97 | 196 | NCT04040322 | Trial comparisons |
| Iloprost Injection, for Intravenous Use vs Placebo: serious adverse events | 1 of 99 | 0 of 97 | 196 | NCT04040322 | Trial comparisons |
| Iloprost vs Placebo: serious adverse events | 3 of 75 | 6 of 77 | 152 | NCT00084409 | Trial comparisons |
| Iloprost (5µg) / Placebo vs Placebo / Iloprost (5 µg): serious adverse events | 0 of 31 | 1 of 33 | 64 | NCT00709956 | Trial comparisons |
| Inhaled Nitric Oxide vs Iloprost: Number of Participants Who Respond After Vasodilator Challenge | 1 of 23 | 4 of 23 | 46 | NCT03044314 | Trial comparisons |
| Iloprost Injection, for Intravenous Use vs Placebo: deaths from any cause | 0 of 17 | 0 of 17 | 34 | NCT03867097 | Trial comparisons |
| Iloprost Injection, for Intravenous Use vs Placebo: serious adverse events | 0 of 17 | 0 of 17 | 34 | NCT03867097 | Trial comparisons |
| Phase 2: Inhaled Iloprost Continuous vs Phase 1: Inhaled Iloprost 3 Doses: Number of Treatment Failures | 0 of 22 | 0 of 5 | 27 | NCT02170519 | Trial comparisons |
| Phase 2: Inhaled Iloprost Continuous vs Phase 1: Inhaled Iloprost 3 Doses: serious adverse events | 0 of 22 | 0 of 5 | 27 | NCT02170519 | Trial comparisons |
1 to 10 of 12
See all 12 comparisons in its trialsPapers from its trials36
The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Tests in its trials0
The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.
None in this release.
Data dates
The date of each source this release read.
Sources 7
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ConductCognition's list of its testsOur own data
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this drug from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/drugs/v1/CHEMBL494
GET https://conductscience.org/api/drugs/v1/CHEMBL494/diseases?page=2